Posts

Summit Touts Updated HARMONi Data Showing Consistent Survival Benefit for Ivonescimab in Western NSCLC Patients

on

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN‑001 in Frontline Ovarian Cancer, Overcoming Historical IL‑12 Safety Barriers

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

Huyabio scores with Opdivo combo in 'milestone' skin cancer trial

on

Hansoh Hits Phase III SCLC Goal

on

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

Pfizer'

on

Pfizer's first new ADC from Seagen acquisition fails Phase 3 NSCLC trial but may live on in earlier lines and combinations

on

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

on

Novocure's bid to move electric fields therapy earlier in glioblastoma falls short

on

Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer

on

Lilly oncology chief went from extremely nervous to blown away by new Jaypirca CLL data

on

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

on

ASCO26: With daraxonrasib in the spotlight, Immuneering makes case for its drug in 1L pancreatic cancer

on

ASCO26: Revolution presents Phase III data that rewrites odds in pancreatic cancer

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Merck's ADC sac‑TMT gets its first global Phase 3 win ahead of schedule

on

Compass Therapeutics Stock Plummets After Mixed Trial Data in Biliary Tract Cancer Study

on

Compass Therapeutics (CMPX) Stock Declines as Tovecimig Trial Misses Overall Survival Endpoint Despite Strong PFS and ORR

on

Revolution Medicines' Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial

on